Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its Q2 financial results on August 3, 2022, before U.S. market opens. Following the report, a conference call is scheduled at 8:30 a.m. ET. The call can be accessed by dialing 1-800-715-9871 (US) or 1-646-307-1963 (international), using passcode 9287305. Interested investors can join via webcast on Pacira's investor page. The company focuses on non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at reducing opioid reliance in pain management.
Pacira BioSciences reported preliminary revenues of $169.4 million for Q2 2022, up from $135.6 million in Q2 2021. Sales were driven by EXPAREL and ZILRETTA, with average daily sales of EXPAREL at 105% of the prior year for Q2. The company is focused on expanding its portfolio of non-opioid pain management solutions. Despite pandemic disruptions, they are optimistic about growth, especially in outpatient settings. The company remains cautious about future guidance due to ongoing challenges, including labor shortages and potential COVID-19 impacts.
Pacira BioSciences and the National Safety Council announced their partnership to launch the Connect2Prevent program, aimed at educating employees and their families on preventing opioid misuse and addiction. The program features a 10-12 week curriculum addressing the risks of opioids, stigma, and alternatives to pain management. This initiative, which starts piloting this summer, encourages meaningful discussions about substance use. Key data highlights the serious risks, such as a 33% higher chance of misuse for those using opioids before high school.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for May 2022, with EXPAREL achieving $44.9 million, a 9% increase from $41.2 million in May 2021. Average daily sales for EXPAREL reached 104% of the prior year, reflecting an increase in utilization. Iovera° sales rose slightly to $1.1 million. CEO Dave Stack highlighted EXPAREL's growth amid ongoing pandemic challenges and noted robust performance of ZILRETTA with over 220 new accounts. The company currently refrains from providing 2022 revenue guidance due to uncertainties from COVID-19 and elective surgery recovery.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:00 AM ET in New York. The live audio of the event can be accessed via the company's website, and a replay will be available for two weeks thereafter.
Pacira is dedicated to providing non-opioid treatment options, including three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº. The company aims to redefine opioid usage and address chronic pain and other debilitating conditions.
Pacira BioSciences partnered with the National Senior Games Association to achieve a GUINNESS WORLD RECORDS title for the Largest Game of Freeze Dance, held on May 16, 2022, with 1,308 participants in Fort Lauderdale, Florida. This event highlighted the company's non-opioid pain relief device, iovera°, which provides up to 90 days of osteoarthritis pain relief. Amber Sears from Pacira emphasized the initiative's role in promoting non-opioid options for chronic pain management, aiming to educate patients about viable alternatives to opioid treatments.
Pacira BioSciences reported preliminary net product sales for April 2022, with EXPAREL achieving $44.8 million, marking a 109% increase in average daily sales compared to April 2021. Sales of iovera° were $1.1 million, down from $1.5 million in the previous year. The company remains financially strong with an adjusted EBITDA of $53.8 million for Q1 2022. Despite ongoing pandemic-related challenges impacting elective surgeries, Pacira's leadership anticipates robust revenue growth. The company has not provided 2022 financial guidance due to uncertainties surrounding COVID-19.
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) will participate in two upcoming healthcare conferences:
- RBC Capital Markets Global Healthcare Conference on May 17 at 8:00 AM ET.
- H.C. Wainwright Global Virtual Investment Conference on May 24 at 7:00 AM ET.
Live audio can be accessed on the company’s website, with replays available for two weeks post-events. Pacira's commitment lies in providing non-opioid pain management solutions.
Pacira BioSciences (Nasdaq: PCRX) reported a strong first quarter of 2022, with total revenues reaching $158 million, marking a 33% increase year-over-year. Net income was $6.8 million or $0.15 per share, while adjusted EBITDA stood at $53.8 million. Significant sales growth for EXPAREL at $129.2 million reflects operational resilience amid COVID-related challenges. The successful integration of the Flexion acquisition contributed to ZILRETTA's sales of $23.6 million. Looking forward, Pacira is optimistic about upcoming clinical studies and new product registrations.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its first quarter financial results on May 4, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. ET, with participation options available for both domestic and international callers. The call will also be accessible via webcast on the company’s investor page. Pacira aims to provide non-opioid pain management solutions and has three commercial treatments: EXPAREL, ZILRETTA, and iovera, focusing on reducing opioid reliance.